r RAL HARNESS Study ATV r 300100 mg qd TDFFTC N 37 N 72 ATVr 300100 mg qd RAL 400 mg bid Design Randomisation 2 1 Openlabel Objective Primary Endpoint proportion with treatment success at W24 ID: 266931
Download Presentation The PPT/PDF document "Switch to ATV/" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
